SK Biopharmaceuticals targets 600 million-person Latin American market with cenobamate launch in Brazil

SK Biopharmaceuticals is partnering with Eurofarma to target the 600 million-person Latin American market. The companies plan to launch the epilepsy treatment cenobamate in Brazil in August. The two companies will strengthen their partnership around five key initiatives, including maximizing the value of cenobamate and collaborating on a CNS pipeline. Following its entry into Peru and Chile, SK Biopharmaceuticals plans to use the Brazil launch as a springboard to expand its business throughout Latin America.